IL280882A - Transgenic bispecific proteins - Google Patents
Transgenic bispecific proteinsInfo
- Publication number
- IL280882A IL280882A IL280882A IL28088221A IL280882A IL 280882 A IL280882 A IL 280882A IL 280882 A IL280882 A IL 280882A IL 28088221 A IL28088221 A IL 28088221A IL 280882 A IL280882 A IL 280882A
- Authority
- IL
- Israel
- Prior art keywords
- bispecific proteins
- engineered bispecific
- engineered
- proteins
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 | |
| PCT/US2019/046705 WO2020037150A2 (en) | 2018-08-16 | 2019-08-15 | Engineered bispecific proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL280882A true IL280882A (en) | 2021-04-29 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL280882A IL280882A (en) | 2018-08-16 | 2021-02-15 | Transgenic bispecific proteins |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (https=) |
| EP (1) | EP3850007A4 (https=) |
| JP (1) | JP7397063B2 (https=) |
| KR (1) | KR20210064199A (https=) |
| CN (1) | CN112839955A (https=) |
| AU (1) | AU2019320803A1 (https=) |
| BR (1) | BR112021002730A2 (https=) |
| CA (1) | CA3109763A1 (https=) |
| EA (1) | EA202190542A1 (https=) |
| IL (1) | IL280882A (https=) |
| MA (1) | MA53616A (https=) |
| MX (1) | MX2021001711A (https=) |
| SG (1) | SG11202101273VA (https=) |
| WO (1) | WO2020037150A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016989A2 (pt) | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| AU2018345303B2 (en) | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| PH12021552002A1 (en) | 2019-02-20 | 2022-09-19 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
| CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
| PE20221465A1 (es) | 2020-01-13 | 2022-09-21 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
| EP4392064A4 (en) * | 2021-08-25 | 2025-12-24 | Denali Therapeutics Inc | MODIFIED ANTI-HER2 BISPECIFIC PROTEINS |
| KR20240116743A (ko) * | 2021-11-09 | 2024-07-30 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| JP2025503437A (ja) * | 2021-12-17 | 2025-02-04 | デナリ セラピューティクス インコーポレイテッド | ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド |
| US12011489B2 (en) * | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| JP2025525792A (ja) | 2022-07-29 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | トランスフェリン受容体１に対して再標的化されるウイルス粒子 |
| CA3263494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE |
| IL318625A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| AU2024317483A1 (en) | 2023-07-28 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP6226752B2 (ja) * | 2012-02-09 | 2017-11-08 | 中外製薬株式会社 | 抗体のＦｃ領域改変体 |
| WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| JP6744856B2 (ja) * | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| WO2016207091A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| MX391086B (es) * | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| BR112019017021A2 (pt) * | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| BR112019016989A2 (pt) * | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| AU2018345303B2 (en) * | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| TW201934573A (zh) * | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| CA3101202A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019320803A1 (en) | 2021-03-11 |
| SG11202101273VA (en) | 2021-03-30 |
| BR112021002730A2 (pt) | 2021-08-10 |
| MX2021001711A (es) | 2021-05-27 |
| KR20210064199A (ko) | 2021-06-02 |
| EA202190542A1 (ru) | 2021-09-07 |
| EP3850007A2 (en) | 2021-07-21 |
| CN112839955A (zh) | 2021-05-25 |
| WO2020037150A2 (en) | 2020-02-20 |
| JP7397063B2 (ja) | 2023-12-12 |
| MA53616A (fr) | 2022-05-04 |
| CA3109763A1 (en) | 2020-02-20 |
| WO2020037150A3 (en) | 2020-10-15 |
| EP3850007A4 (en) | 2022-08-10 |
| JP2021533779A (ja) | 2021-12-09 |
| US20220017634A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280882A (en) | Transgenic bispecific proteins | |
| IL279235A (en) | DLL3-CD3 bispecific antibodies | |
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL280013A (en) | Anti-IL36R antibodies | |
| IL279352A (en) | IL-11RA antibodies | |
| SG11202013138RA (en) | Anti-steap1 antigen-binding protein | |
| ZA202004908B (en) | Bispecific antibody | |
| IL278010A (en) | Antibodies to galectin 10 | |
| GB201710838D0 (en) | Bispecific antibodies | |
| GB201905150D0 (en) | Ant-ige antibodies | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| IL277030A (en) | Antibodies | |
| DK3737402T3 (en) | Modificeret protein | |
| IL284584A (en) | Anti-tigit antibodies | |
| IL282355A (en) | Bispecific antibodies directed to exosomes | |
| IL286757A (en) | Antibodies in specific | |
| IL269577B (en) | Bispecific antibodies anti–pd–l1–anti–tim–3 | |
| IL274676A (en) | The bispecific antigen binding composition | |
| SG11202102114UA (en) | Anti-klrg1 antibodies | |
| ZA202206008B (en) | Bispecific anti-ccl2 antibodies | |
| GB201900732D0 (en) | Antibodies | |
| GB201806084D0 (en) | Antibodies | |
| EP3901173A4 (en) | BISPECIFIC PROTEIN | |
| GB201917480D0 (en) | Antibodies | |
| GB2598698B (en) | Affinity-maturated anti-ASICIa antibodies |